Drugs / IMP3-saRNA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07561723 | Apr 2026 → Apr 2028 expected | non-small cell lung carcinoma | West China Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMP3-saRNA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07561723 ↗ |
| Known as | YMN-136 | “IMP3-saRNA (YMN-136) vaccine is a biological vaccine product prepared from IMP3 self-amplifying RNA and lipid nanoparticles.” NCT07561723 ↗ |
| Modality | Small activating RNA (saRNA) | “IMP3 self-amplifying RNA” NCT07561723 ↗ |
| Route | Intramuscular | “The vaccine will be administered by intramuscular injection.” NCT07561723 ↗ |